Navigation Links
Denham Capital to Invest $60 Million in VitAG, Recycler of Municipal Biosolids
Date:8/6/2008

BOSTON and BEECH ISLAND, S.C., Aug. 6 /PRNewswire/ -- Denham Capital ("Denham") announced today that it will invest up to $60 million in VitAG Corporation ("VitAG"). VitAG technology converts municipal biosolids into a value-added high-nitrogen fertilizer product capable of competing with and outperforming conventional fertilizers. The investment will fund the construction of multiple biosolids-to-fertilizer manufacturing plants.

"Denham's investment in VitAG is an opportunity for Denham to participate in the global fertilizer market in an environmentally sensitive manner," said Bill Zartler, a Managing Partner of Denham Capital. "We look forward to partnering with the innovative and experienced VitAG team on the execution of their business plan."

The VitAG process creates a sustainable and economic solution for recycling biosolids into a commercially viable fertilizer. The proprietary VitAG technology creates a granular, high-value fertilizer product that meets and exceeds the USEPA Class A and Exceptional Quality standards for biosolids-containing products. In addition, the small footprint of a VitAG manufacturing facility allows it to be located at or near existing municipal wastewater treatment plants and be sized according to the treatment plant's biosolids output, thus reducing logistical concerns and liability traditionally associated with the transportation of biosolids.

"The key to VitAG's technology is that it is environmentally-friendly," said Jeffrey C. Burnham, PhD, President and CEO of VitAG Corp. "In addition to use in traditional fertilizer markets for crops, turf, and ornamental production, VitAG fertilizer is ideal for boosting production of bio-energy specific crops," said Burnham.

VitAG has formed strategic partnerships with leading consulting, engineering and fertilizer equipment companies for the planning, engineering and construction of the VitAG facilities, and for the design and fabrication of the process equipment, respectively; and with Ferrate Treatment Technologies, LLC, manufacturer of a unique biosolids deodorizer.

About Denham Capital:

Denham Capital is a leading global private equity firm, with offices in Boston, Houston, Short Hills, New Jersey and London. With approximately $4.3 billion of invested and committed capital, Denham makes direct investments in all segments of the energy and commodities value chain, including oil and gas, mining, timber, power, carbon assets and energy-related infrastructure and services. The firm invests globally, with investments currently in the US, Canada, South America, Europe, Russia/CIS, Asia and Australia, and across all parts of the capital structure and all stages of the corporate and asset lifecycle, from development projects to mature, operating businesses. Denham typically targets investments in the $50 million to $250 million range. For more information about Denham Capital, visit HYPERLINK "http://www.denhamcapital.com/" http://www.denhamcapital.com. Denham Capital does not provide investment advisory services to the public.

Contacts:

VitAG Corporation, Jeffrey C. Burnham, PhD, (803) 652-0990, jburnham@vitagcorp.com

Denham Capital Management, Gina Sorice, CJP Communications, (212) 279-3115 ext 243, gsorice@cjpcom.com


'/>"/>
SOURCE Denham Capital; VitAG Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Bionovo to Present at BMO Capital Markets 2008 Focus on Healthcare Conference
2. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
3. Sangamo BioSciences to Present at the BMO Capital Markets Focus on Healthcare Conference
4. VNUS Medical Technologies to Present at BMO Capital Markets 2008 Focus on Healthcare Conference
5. 2008 Kansas Day of Innovation Featuring the Fifth Annual Great Plains Capital Conference Scheduled for September
6. Arbel Medical has Completed a $4.5 million Round of Capital Raising led by Giza Venture Capital Fund
7. Insmed Retains RBC Capital Markets as Strategic Financial Advisor
8. Commercial Launch of Lexiscan(TM) (Regadenoson) Injection Triggers $10 Million Milestone Payment from TPG-Axon Capital to CV Therapeutics
9. WorldHeart Enters into a Recapitalization Agreement and Receives Bridge Financing
10. Immtech Pharmaceuticals and Beijing Capital Medical University Announce Joint Venture to Provide Contract Research Services in China
11. Deloitte Agrees to Acquire Recombinant Capital, A Leading Life Sciences Subscription Database and Advisory Services Firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... June 20, 2017 , ... National executive search ... with extensive assay development and biomarker expertise, as VP of Scientific Affairs at ... specializing in bio-analytical assay development and sample testing services. The organization acts as ...
(Date:6/19/2017)... NJ (PRWEB) , ... June 19, 2017 , ... ... for overseeing all service activities supporting EDETEK’s products including training, implementation, support, and ... experience to his new role. He has previously held leadership roles for service ...
(Date:6/19/2017)... ... ... A colony of healthy honey bees is like a superorganism--individual bees provide the ... nutrients necessary for growth and survival. Better nutrition gives the colony a strong immune ... decline in honey bee health. Sick and weakened bees diminish the colony's resiliency, leading ...
(Date:6/16/2017)... Rocky Hill, CT (PRWEB) , ... June 16, 2017 , ... ... of last night’s Entrepreneur Innovation Awards (EIA), held at The LOFT at Chelsea Piers ... their innovative project ideas to a panel of judges for an opportunity to secure ...
Breaking Biology Technology:
(Date:4/11/2017)... Apr. 11, 2017 Research and Markets has ... report to their offering. ... The global eye tracking market to grow at a CAGR of ... Eye Tracking Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
Breaking Biology News(10 mins):